NCT03010124Recruiting
Prognostic and Predictive Biomarkers in Ovarian Cancers
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
The investigators therefore propose to conduct a biological study of prospectively collected patient tumour samples, ascites, blood and other residual samples (feces, urine, vaginal smear) throughout the disease course where markers (at diagnosis and their change with treatment) will be correlated to outcome in order to investigate how genetic diversity in OC prior to treatment and adaptation following treatment contribute to chemotherapy resistance. In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex vivo DNA repair functional assays and isolated in primary culture (and established as xenografts) for target validation experiments.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- First submitted
- 13 Dec 2016
- Start date
- 26 Sept 2016
- Primary completion date
- 30 Sept 2030
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Diseases
- Ovarian cancer
- NCT number
- NCT03010124
What you commit to
- Study type: Interventional
- Planned participants: 350
- From 26 Sept 2016 to the primary completion date, 30 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment;
- Coagulation abnormalities that contra-indicates the biopsy
Who the study is looking for
- New patient with a diagnosis of OC, or
- Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or
- Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease.
- Signed informed consent
- Age ≥ 18
- Patient affiliated to a social security regimen or beneficiary of the same
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.